A77: Clinical and Laboratory Features and Systemic Lupus Erythematous Disease Activity Index 2000 (SLEDAI 2K) at Onset and Follow Up in a Cohort of 109 Paediatric Lupus Patients From a Tertiary Level Centre in India

Background/Purpose: Pediatric Rheumatology is a relatively new branch in India. To the best of our knowledge, this is the first paper that has studied SLEDAI 2K in 109 children with SLE at onset, 6 months and annually thereafter for a median follow up of 38 months. Methods: In our unit, disease activity of all children with lupus is captured on disease assessment proformas and completed every 3–6 months. This form captures demographics, clinical assessment, lab results and therapy. All paediatric lupus patients (diagnosed per the ACR criteria 1992) with disease onset <18 years seen at our unit from 2001 were included. The clinical and laboratory features at presentation and the SLEDAI 2K was captured at onset, 6 months and thereafter annually. We chose SLE 2K as an outcome measure as it captures new, recurrent and ongoing disease activity ([1][Chee‐Seng Yee, 2011]). The aims of the study were To detail the presentation of cSLE from India To study the SLEDAI 2K at onset and follow up To compare the data from India to that available from the West. available from the West. Results: Demographics: 109 patients identified, 90 were females. The median age at onset was 11.4 (3.4‐18) years and median age at diagnosis 12.1 (3.5‐19). The median duration of follow up was 38 months (3‐152). Clinical presentation at onset: As in table . Nine children had MAS at onset. Table 1.Feature % positiveConstitutionalfever 83 arthralgia 80 Fatigue 70 myalgia 55 weight loss 43Lupus featuresmalar rash 62 arthritis 60 alopecia 59 mucositis 56 photosensitivity 39 vasculitis 38 nephritis 35 lymphadenopathy 33 neurologic 17 effusion 14Labs at onset : ANA positive in 97%, DsDNA in 80%, low complements seen in 84%. Anemia, leucopenia and thrombocytopenia present in 37, 31, and 28% respectively. APL antibodies positive in 28%. SLEDAI 2K at onset and follow up : TableSLEDAI 2K in a Cohort of cSLE Patients at Onset and 5 Year Follow Updisease duration months no of patients Median SLEDAI % pts with SLEDAI <4 SLEDAI Range0 109 16 2 1 to 52 6 107 2 56 0 to 28 12 97 2 66 0 to 16 24 77 2 70 0 to 28 36 58 2 71 0 to 24 48 44 0 75 0 to 50 60 37 2 70 0 to 12Median SLEDAI 2K 16 at onset and subsequently all median SLEDAIs were <4. Patients with inactive disease (SLEDAI 2K <4) ([1][Chee‐Seng Yee, 2011]) 70–75% after the 6 months. Nineteen patients had a new organ involvement 6 months after disease onset, eight nephritis. Follow up: 54 patients had no flare, 27–1 flare and 28 patients had 2–5 flares each. One patient died, no patient had renal failure/transplant. Seven patients had hypothyroidism and 1 had celiac disease. Comparison with Western data : Of 256 patients with cSLE described from Toronto, the mean SLEDAI was 13 at onset and 2.9 at one year, very similar to our study ([2][Linda t. Hiraki, 2008]). The cohort from Israel studied 102 patients with a higher SLEDAI of 17 at onset, 7.6 at 5 years with 5 patients in renal failure ([3][Uziel. Y, 2007]). Conclusion: 80% of patients had fever and 33% had nephritis at onset. The disease burden at onset was high; median SLEDAI fell to <4 within 6 months and remained low through follow up. 17% had new organ involvement after 6 months. 50% had no disease flare. The disease burden is similar to that described in the West.